Global Glaucoma Eye Drops Market Overview:
Glaucoma is caused by a build-up of fluid in the eye called aqueous humor, or simply aqueous humor however, glaucoma is permanent that cannot be reversed but medicine and surgery help to stop further damage. This causes an increase in pressure in the eye (intraocular or intraocular pressure), which damages the optic nerve and leads to loss of vision. Eye drops are generally known to be the most common treatment for glaucoma. They decrease the amount of fluid in the eye by either increasing the flow of fluid from the eye or decreasing the amount of fluid produced. Medicines used to treat glaucoma are classified according to their active ingredient. These include prostaglandin analogs, beta-blockers, alpha agonists, carbonic anhydrase inhibitors, and rho kinase inhibitors. In addition, combination products are available for patients who need more than one type of medication. An older class of drugs, the cholinergic agonists (like pilocarpine), are not widely used today because of their side effects. Currently, eye drops are often the first choice for treating patients in the United States. For many people, a combination of medication and laser treatment can safely control eye pressure for years. Eye drops used to treat glaucoma lower eye pressure by helping the eye fluid to drain better and/or by reducing the amount of fluid the eye makes. World Glaucoma Week (WGW) is a joint global initiative of the World Glaucoma Association (WGA) and the World Glaucoma Patients Association (WGPA), to raise awareness of glaucoma. Glaucoma is the second foremost cause of blindness and the leading cause of irreversible blindness globally, with an estimated 4.5 million blinded by the condition. It was estimated that the number of people with glaucoma will increase to 79.6 million by 2020.
- The Increasing Number of Product Launches and Approvals
- Increasing Robust Product Pipeline for Treatment of Glaucoma
- Increasing Research in Prostaglandin Analogs
- Side Effects like Blurred or Dimmed Vision and Nearsightedness
- Raising Awareness of Glaucoma and Rising Demand for Glaucoma Drugs
- Availability of Alternatives Treatments
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Merck & Co., Inc. (United States), Allergan Plc. (United States), Novartis AG (Switzerland), Teva Pharmaceutical Industry (Israel), Pfizer, Inc. (United States), Bausch & Lomb Inc. (United States), Inotek Pharmaceutical (United States), Jadran-galenski laboratorij d.d. (Croatia), Aerie Pharmaceutical (United States) and Mylan N.V. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Glaucoma Eye Drops market by 2026. Considering Market by Composition, the sub-segment i.e. Preservative Free will boost the Glaucoma Eye Drops market. Considering Market by Disease Type, the sub-segment i.e. Open-Angle will boost the Glaucoma Eye Drops market. Considering Market by Distribution Channel, the sub-segment i.e. Online will boost the Glaucoma Eye Drops market.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Glaucoma Eye Drops market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Glaucoma Eye Drops market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Glaucoma Eye Drop, Suppliers of Glaucoma Eye Drop, Wholesalers, Distributors, and Retailers of Glaucoma Eye Drop, Pharmaceutical Industry, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.